Docetaxel Injection is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC, Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable…
From the U.S. FDA-approved label for Docetaxel. Full label: DailyMed.
Docetaxel Injection is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC, Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC, Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer, Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction, Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
From the U.S. FDA-approved label for Docetaxel. Full label: DailyMed.
For all indications, toxicities may warrant dosage adjustments. Administer in a facility equipped to manage possible complications (e.g., anaphylaxis). Administer in a facility equipped to manage possible complications (e.g., anaphylaxis).
Directions from the U.S. FDA-approved label for Docetaxel — your doctor or pharmacist may advise differently.
Docetaxel Injection is contraindicated in patients with: neutrophil counts of <1500 cells/mm 3., a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80. Severe reactions, including anaphylaxis, have occurred., Hypersensitivity to docetaxel or polysorbate 80, Neutrophil counts of <1500 cells/mm 3
Excerpt from the U.S. FDA-approved label for Docetaxel. Talk to a pharmacist or doctor before use.
Second primary malignancies: In patients treated with Docetaxel Injection-containing regimens, monitor for delayed AML, MDS, NHL, and renal cancer., Cutaneous reactions: Reactions including erythema of the extremities with edema followed by desquamation may occur. Severe cutaneous adverse reactions have been reported. Severe skin toxicity may require dose adjustment or permanent treatment discontinuation., Neurologic reactions: Reactions including paresthesia, dysesthesia, and pain may occur.
Warnings and precautions excerpt from the U.S. FDA-approved label for Docetaxel — not a complete list. Talk to a pharmacist or doctor before use.
The most serious adverse reactions from docetaxel are: Toxic Deaths, Hepatic Impairment, Hematologic Effects, Enterocolitis and Neutropenic Colitis, Hypersensitivity Reactions, Fluid Retention, Second Primary Malignancies, Cutaneous Reactions, Neurologic Reactions, Eye Disorders, Asthenia, Alcohol Content The most common adverse reactions across all docetaxel indications are infections, neutropenia, anemia, febrile…
Excerpt from the U.S. FDA-approved label for Docetaxel — not a complete list. Talk to a pharmacist or doctor about side effects.
9 brands · 4 makers in the NepalDoc catalog — see the full Docetaxel guide →
16.2 Storage Store at 20°C to 25°C (68°F to 77°F).. Retain in the original package to protect from light. Freezing does not adversely affect the product. After first use and following multiple needle entries and product withdrawals, Docetaxel Injection multiple-dose vials are stable for up to 28 days when stored between 2°C and 8°C (36°F and 46°F) and protected from light.
Storage information from the U.S. FDA-approved label for Docetaxel.
What is C-Celtere?
C-Celtere 20mg/0.5ml Injection is a Docetaxel medicine made by Celon Lab. It comes as 20mg/0.5ml Injection.
What is the generic name of C-Celtere?
The generic name of C-Celtere is Docetaxel.
Which brands of Docetaxel are available in Nepal?
9 brands of Docetaxel are listed in the NepalDoc catalog, from 4 makers — including C-Celtere 80MG/2ML Injection, Daxotel 120mg Injection, Daxotel 20mg Injection, Docetere 120mg Injection, Docetere 20mg Injection, Docetere 80mg Injection.
What are the side effects of Docetaxel?
The most serious adverse reactions from docetaxel are: Toxic Deaths, Hepatic Impairment, Hematologic Effects, Enterocolitis and Neutropenic Colitis, Hypersensitivity Reactions, Fluid Retention, Second Primary Malignancies, Cutaneous Reactions, Neurologic Reactions, Eye Disorders, Asthenia, Alcohol Content The most common adverse reactions across all docetaxel indications are infections, neutropenia, anemia, febrile…
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.
